Search research articles
Contact Us
Filters
Showing results (91-100 of 124) with videos related to
Page
of 13
Sort By:
Oncotarget
|
April 13, 2018
BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer
Sarah Shields, Emer Conroy, Tony O'Grady, et al.
Oncotarget
|
May 30, 2019
Correction: BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer
Sarah Shields, Emer Conroy, Tony O'Grady, et al.
Trials
|
April 4, 2024
Does the use of higher versus lower oxygen concentration improve neurodevelopmental outcomes at 18-24 months in very low birthweight infants?
Georg M Schmölzer, Elizabeth V Asztalos, Marc Beltempo, et al.
Plos One
|
March 23, 2017
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
Anne M Plomgaard, Thomas Alderliesten, Topun Austin, et al.
Frontiers in Molecular Neuroscience
|
September 27, 2021
Novel Point-of-Care Diagnostic Method for Neonatal Encephalopathy Using Purine Nucleosides
Edward Beamer, Mary Isabel O'Dea, Aisling A Garvey, et al.
Pediatric Research
|
July 8, 2016
Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN)
Willem P de Boode, Yogen Singh, Samir Gupta, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition
|
December 10, 2015
The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings
Joan Riera, Simon Hyttel-Sorensen, María Carmen Bravo, et al.
Pediatric Research
|
December 19, 2015
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury
Anne M Plomgaard, Wim van Oeveren, Tue H Petersen, et al.
Neonatology
|
August 8, 2013
The SafeBoosC phase II randomised clinical trial: a treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants
Adelina Pellicer, Gorm Greisen, Manon Benders, et al.
The Pediatric Infectious Disease Journal
|
September 18, 2015
Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study
Margaret Sheridan-Pereira, Joan Murphy, Julie Sloan, et al.
Page
of 13
Search research articles
Search
Showing results (91-100 of 124) with videos related to
Sort By:
Page
of 13
Oncotarget
|
April 13, 2018
BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer
Sarah Shields, Emer Conroy, Tony O'Grady, et al.
Oncotarget
|
May 30, 2019
Correction: BAG3 promotes tumour cell proliferation by regulating EGFR signal transduction pathways in triple negative breast cancer
Sarah Shields, Emer Conroy, Tony O'Grady, et al.
Trials
|
April 4, 2024
Does the use of higher versus lower oxygen concentration improve neurodevelopmental outcomes at 18-24 months in very low birthweight infants?
Georg M Schmölzer, Elizabeth V Asztalos, Marc Beltempo, et al.
Plos One
|
March 23, 2017
Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial
Anne M Plomgaard, Thomas Alderliesten, Topun Austin, et al.
Frontiers in Molecular Neuroscience
|
September 27, 2021
Novel Point-of-Care Diagnostic Method for Neonatal Encephalopathy Using Purine Nucleosides
Edward Beamer, Mary Isabel O'Dea, Aisling A Garvey, et al.
Pediatric Research
|
July 8, 2016
Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN)
Willem P de Boode, Yogen Singh, Samir Gupta, et al.
Archives of Disease in Childhood. Fetal and Neonatal Edition
|
December 10, 2015
The SafeBoosC phase II clinical trial: an analysis of the interventions related with the oximeter readings
Joan Riera, Simon Hyttel-Sorensen, María Carmen Bravo, et al.
Pediatric Research
|
December 19, 2015
The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury
Anne M Plomgaard, Wim van Oeveren, Tue H Petersen, et al.
Neonatology
|
August 8, 2013
The SafeBoosC phase II randomised clinical trial: a treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants
Adelina Pellicer, Gorm Greisen, Manon Benders, et al.
The Pediatric Infectious Disease Journal
|
September 18, 2015
Respiratory Syncytial Virus Preterm (32-36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland: A Prospective Study
Margaret Sheridan-Pereira, Joan Murphy, Julie Sloan, et al.
Page
of 13